In this timely episode, I am excited to share the brand-new 2025 clinical guidelines for treating Genitourinary Syndrome of Menopause (GSM)—a long-overdue update that prioritizes shared decision making and patient-centered care. Whether you’re a patient navigating vaginal dryness, bladder issues, or recurrent UTIs, or a clinician looking to stay current, this episode is a must-listen. We'll go over the science, dispel myths about estrogen safety, and learn how these guidelines shift the conversation around midlife women’s health.
What you’ll learn in this episode:
💡 Why the new GSM guidelines are revolutionary—and long overdue
🧠 What shared decision making really means in patient care
🌸 The real truth about vaginal estrogen safety (yes, even for breast cancer survivors)
🔍 How low hormones—estrogen AND testosterone—cause GSM symptoms
🧴 Treatment options beyond estrogen: DHEA, Ospemifene, and vaginal testosterone
🚽 How vaginal estrogen reduces bladder symptoms and cuts recurrent UTIs by 52%
🧬 Why package inserts are misleading—and how FDA labeling has confused patients for years
📢 A call to action for both providers and patients: know your options and advocate for your quality of life
This episode is a critical listen for both patients and providers alike. Whether you're experiencing GSM symptoms yourself or helping women manage this often-overlooked condition, the insights and updates shared here are essential for making empowered, evidence-based decisions.
Podden och tillhörande omslagsbild på den här sidan tillhör
Kristin Jackson. Innehållet i podden är skapat av Kristin Jackson och inte av,
eller tillsammans med, Poddtoppen.
